Intercellular Adhesion Molecule 1 Gene Polymorphisms in Graves’ Disease

It was recently suggested that genetic factors could play a major role in the development of Graves’ disease (GD). The aim of the present study was to evaluate the frequency of the c.721G→A polymorphism and the c.1405A→G polymorphism of the intercellular adhesion molecule 1 (ICAM-1) gene in subjects...

Full description

Saved in:
Bibliographic Details
Published inThe journal of clinical endocrinology and metabolism Vol. 88; no. 10; pp. 4945 - 4949
Main Authors Kretowski, Adam, Wawrusiewicz, Natalia, Mironczuk, Katarzyna, Mysliwiec, Janusz, Kretowska, Malgorzata, Kinalska, Ida
Format Journal Article
LanguageEnglish
Published Bethesda, MD Oxford University Press 01.10.2003
Copyright by The Endocrine Society
Endocrine Society
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:It was recently suggested that genetic factors could play a major role in the development of Graves’ disease (GD). The aim of the present study was to evaluate the frequency of the c.721G→A polymorphism and the c.1405A→G polymorphism of the intercellular adhesion molecule 1 (ICAM-1) gene in subjects with GD compared with that in healthy controls, because ICAM-1 was found to play a key role in lymphocyte infiltration into the thyroid gland and the concentration of the soluble form of ICAM-1 correlates significantly with the clinical activity and treatment status in GD. We have analyzed the association of ICAM-1 polymorphisms with the age at onset of GD and the presence of ophthalmopathy. In a group of 235 patients with GD and 211 healthy controls we have shown that polymorphism at position c.721G→A is associated with an earlier age of GD onset and that the c.1405A→G polymorphism of the ICAM-1 gene could predispose to Graves’ ophthalmopathy. This suggests that G241R and K469E amino acid substitutions in the ICAM-1 molecule could influence the intensity/duration of the autoimmunity process and the infiltration of orbital tissues. It could be speculated that therapy that modulates ICAM-1 function may delay the onset and/or prolong the remission and/or have an influence on clinical manifestations of GD.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:0021-972X
1945-7197
DOI:10.1210/jc.2003-030131